Ginkgo Bioworks Holdings Inc (NYSE:DNA) price closed lower on Monday, April 15, dropping -5.94% below its previous close.
A look at the daily price movement shows that the last close reads $1.01. The company’s 5Y monthly beta was ticking 1.36. Taking into account the 52-week price action we note that the stock hit a 52-week high of $2.55 and 52-week low of $0.99. The stock subtracted -10.38% on its value in the past month.
Ginkgo Bioworks Holdings Inc, which has a market valuation of $1.93 billion, is expected to release its quarterly earnings report Mar 01, 2024 – Mar 05, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give DNA a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
The overview shows that DNA’s price is at present -13.24% off the SMA20 and -22.76% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 35.13, with weekly volatility standing at 8.98%. The indicator jumps to 7.15% when calculated based on the past 30 days. Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s beta value is holding at 1.37, while the average true range (ATR) indicator is currently reading 0.09.
An analysis of the Ginkgo Bioworks Holdings Inc (NYSE:DNA) stock in terms of its daily trading volume indicates that the 3-month average is 22.34 million.
Current records show that the company has 1.53B in outstanding shares. The insiders’ percentage holdings are 33.65% of outstanding shares while the percentage share held by institutions stands at 58.66%. But the -43.79% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
